Expression and Significance of HMGB1, RAGE, and IL-6 in Peripheral Blood of Patients with Henoch-Schonlein Purpura

Abstract

Abstract: Objective To investigate the expression of HMGB1, RAGE, and IL-6 in patients with Henoch-Schonlein purpura (HSP), and to explore their roles in the development of HSP. Methods A total of 80 patients diagnosed with Henoch-Schonlein purpura at the Affiliated Hospital of Chengde Medical University from January 2022 to July 2024 were selected as the research objects. According to the results of the urine examination, patients were split into renal purpura group and non-renal purpura group, and a health examination population in the same period were selected as the control group. The expression of HMGB1, RAGE, and IL-6 was detected by ELISA. Non-parametric test and binary logistic regression model were utilized to analyze the data, and the ROC curve was adopted to analyze the predictive value of indicators for renal purpura. Results The expression levels of HMGB1 and IL-6 were highest in the renal purpura group, and the non-renal purpura group was higher than the control group (P<0.05). The expression levels of RAGE showed little difference between the renal purpura group and the non-renal purpura group (P>0.05), with both groups being higher than the control group (P<0.05). Binary logistic regression analysis shows that the increase in HMGB1 and IL-6 is statistically significant in the occurrence of renal purpura. The ROC curve indicates that the rise in HMGB1 and IL-6 demonstrates significant clinical significance for the early assessment of kidney damage. Conclusion HMGB1, RAGE, and IL-6 may be involved in the occurrence and development of HSP. HMGB1 is expected to be a potential target for the treatment of HSP. The combined detection of HMGB1 and IL-6 has high clinical value for early evaluation of the occurrence of renal purpura.

Key words: Henoch-Schonlein purpura, Henoch-schonlein purpura nephritis, HMGB1, RAGE, IL-6

摘要： 目的研究HMGB1、RAGE和IL-6在过敏性紫癜（HSP）中的表达水平,探讨其在疾病发生发展中的作用。方法选取2022年1月~2024年7月期间于承德医学院附属医院确诊为过敏性紫癜患者共80例为研究对象,根据尿液检查结果分为肾型紫癜组和非肾型紫癜组,选取同期体检人群为对照组。采用ELISA法检测HMGB1、RAGE和IL-6的表达。采用非参数检验和二元logistic回归模型对结果分析,ROC曲线分析指标对肾型紫癜的预测价值。结果 HMGB1和IL-6在肾型紫癜组表达水平最高,非肾型紫癜组高于对照组（P<0.05）。RAGE表达水平在肾型紫癜组和非肾型紫癜组间比较差异不大（P>0.05）,2组均高于对照组（P<0.05）。二元Logistic回归分析显示HMGB1和IL-6的升高与肾型紫癜的发生具有统计学意义。ROC曲线显示HMGB1和IL-6的升高对于早期评估肾脏损伤具有较好的临床意义。结论 HMGB1、RAGE、IL-6可能参与了HSP的发生和发展,HMGB1有望成为HSP治疗的潜在靶点,HMGB1和IL-6两者联合检测对早期评估肾型紫癜的发生具有较高的临床价值。

关键词: 过敏性紫癜, 紫癜性肾炎, HMGB1, RAGE, IL-6

CLC Number:

R751

WANG Yi-ke, SONG Xi-ning, CHEN Wei, LI Bao-qiang. Expression and Significance of HMGB1, RAGE, and IL-6 in Peripheral Blood of Patients with Henoch-Schonlein Purpura[J]. Journal of Chengde Medical University, 2025, 42(3): 191-195.

王以可, 宋浠宁, 陈伟, 李保强. HMGB1、RAGE和IL-6在过敏性紫癜患者外周血中的表达和意义[J]. 承德医学院学报, 2025, 42(3): 191-195.

Add to citation manager EndNote|Ris|BibTeX

URL: http://tougao.cdmc.edu.cn:8088/EN/

http://tougao.cdmc.edu.cn:8088/EN/Y2025/V42/I3/191

References

[1] Song Y, Huang X, Yu G, et al.Pathogenesis of IgA Vasculitis: An Up-To-Date Review[J]. Front Immunol, 2021, 12: 771619.
[2] Parums DV.A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future[J]. Med Sci Monit, 2024, 30: e943912.
[3] Reamy BV, Servey JT, Williams PM. Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review[J]. Am Fam Physician, 2020, 102(4): 229-233.
[4] Magna M, Pisetsky DS.The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases[J]. Mol Med, 2014, 20(1): 138-146.
[5] Yang H, Wang H, Andersson U.Targeting Inflammation Driven by HMGB1[J]. Front Immunol, 2020, 11: 484.
[6] Ozen S, Pistorio A, Iusan SM, et al.EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria[J]. Ann Rheum Dis, 2010, 69(5): 798-806.
[7] Pillebout E, Sunderkötter C.IgA vasculitis[J]. Semin Immunopathol, 2021, 43(5): 729-738.
[8] Chen R, Kang R, Tang D.The mechanism of HMGB1 secretion and release[J]. Exp Mol Med, 2022, 54(2): 91-102.
[9] Xue J, Suarez JS, Minaai M, et al.HMGB1 as a therapeutic target in disease[J]. J Cell Physiol, 2021, 236(5): 3406-3419.
[10] Hudson BI, Lippman ME.Targeting RAGE Signaling in Inflammatory Disease[J]. Annu Rev Med, 2018, 69: 349-364.
[11] Singh H, Agrawal DK.Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases[J]. Molecules, 2022, 27(21): 7311.
[12] Qin J, Zhang L, Ke B, et al.Causal relationships between circulating inflammatory factors and IgA vasculitis: a bidirectional Mendelian randomization study[J]. Front Immunol, 2023, 14: 1248325.
[13] Pillebout E, Jamin A, Ayari H, et al.Biomarkers of IgA vasculitis nephritis in children[J]. PLoS One, 2017, 12(11): e0188718.
[14] Held M, Kozmar A, Sestan M, et al.Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV)[J]. Int J Mol Sci, 2024, 25(8): 4383.
[15] Chen T, Guo ZP, Wang WJ, et al.Increased serum HMGB1 levels in patients with Henoch-Schönlein purpura[J]. Exp Dermatol, 2014, 23(6): 419-423.
[16] 阮小霞,罗冲,安云飞,等. 过敏性紫癜患儿血清高迁移率族蛋白B1表达及意义[J]. 中国实用儿科杂志,2021,36(7):503-507.
[17] Batnozic Varga M, Held M, Wagner J, et al.The Association of HMGB1 and RAGE Gene Polymorphisms with IgA Vasculitis[J]. Biochem Genet, 2024, 62(3): 2268-2278.
[18] Kang S, Narazaki M, Metwally H, et al.Historical overview of the interleukin-6 family cytokine[J]. J Exp Med, 2020, 217(5): e20190347.
[19] Sugiyama M, Wada Y, Kanazawa N, et al.A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy[J]. PLoS One, 2020, 15(4): e0232194.
[20] Hastings MC, Rizk DV, Kiryluk K, et al.IgA vasculitis with nephritis: update of pathogenesis with clinical implications[J]. Pediatr Nephrol, 2022, 37(4): 719-733.
[21] Wang J, Fu L, Yang H, et al.The Anti-inflammatory Effects of HMGB1 Blockades in a Mouse Model of Cutaneous Vasculitis[J]. Front Immunol, 2020, 11: 2032.